WO2021104391A1 - 一种齐墩果烷苯丙烯酰胺衍生物及其制备方法和用途 - Google Patents

一种齐墩果烷苯丙烯酰胺衍生物及其制备方法和用途 Download PDF

Info

Publication number
WO2021104391A1
WO2021104391A1 PCT/CN2020/131887 CN2020131887W WO2021104391A1 WO 2021104391 A1 WO2021104391 A1 WO 2021104391A1 CN 2020131887 W CN2020131887 W CN 2020131887W WO 2021104391 A1 WO2021104391 A1 WO 2021104391A1
Authority
WO
WIPO (PCT)
Prior art keywords
cyano
cancer
compound
diene
dioxooleanane
Prior art date
Application number
PCT/CN2020/131887
Other languages
English (en)
French (fr)
Inventor
张贵民
梁红宝
陈莉
赵桂芳
赵子豪
卢小艳
孙成宏
Original Assignee
鲁南制药集团股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 鲁南制药集团股份有限公司 filed Critical 鲁南制药集团股份有限公司
Priority to JP2022531563A priority Critical patent/JP2023504428A/ja
Priority to EP20894763.0A priority patent/EP4067367A4/en
Priority to KR1020227018564A priority patent/KR20220104734A/ko
Priority to CN202080079360.9A priority patent/CN114729001A/zh
Priority to US17/779,165 priority patent/US20230023332A1/en
Publication of WO2021104391A1 publication Critical patent/WO2021104391A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Definitions

  • the present invention relates to the field of medicinal chemistry and pharmacotherapy.
  • the content includes a class of 2-cyano-3,12-dioxoolean-1,9(11)-diene-17-benzeneacrylamide compounds and Its preparation method; the present invention also relates to the application of the new compound in the preparation of anticancer drugs.
  • Oleanolic acid is a natural product of pentacyclic triterpenoids. It is widely distributed in the plant kingdom. It is an effective component of many traditional Chinese medicines and has a wide range of biological activities. Structure optimization based on OA has always been one of the hotspots in natural medicine chemistry research.
  • CDDO and its derivatives are semi-synthetic OA derivatives with the strongest anti-tumor and anti-inflammatory activities found so far. Different from single-target drugs, CDDOs have the characteristics of multi-function, multi-target, acting on the entire cell signaling pathway, and can exert anti-tumor effects from multiple links. Therefore, high activity and resistance to drug resistance are the advantages of such derivatives.
  • CDDO-Me methyl ester derivative of CDDO (2-cyano-3,12-dioxooleanane-1,9(11)-diene-28-acid methyl ester
  • Method methyl Bardoxolone Metal
  • CERT00529438 a phase I clinical trial
  • NCT00508807 a phase I clinical trial
  • CDDO-Me was approved by the FDA in 2008 to evaluate the treatment of chronic kidney disease (Chronic Kidney Disease, CUK) caused by type 2 diabetes (NCT00664027).
  • CUK chronic Kidney Disease
  • CDDO-Me has good anti-tumor activity, its myocardial toxicity is still worthy of attention. It will be of great practical significance if it can retain or enhance the activity of this type of compound and reduce its toxicity through the necessary modification and transformation.
  • the present invention discloses for the first time a class of 2-cyano-3,12-dioxooleanane-1,9(11)-diene-17-benzeneacrylamide compound and its preparation method and medical use.
  • the preparation method of such derivatives in the invention has the following advantages: the raw materials are cheap and easy to obtain, the reagents are environmentally friendly and low-toxic, the conditions are mild and easy to control, the post-processing is convenient and simple, and it is also practical and universal.
  • the results of pharmacological experiments show that the compound of the present invention has excellent anti-tumor activity, which is higher than or equivalent to CDDO-Me; the myocardial toxicity of some compounds is significantly reduced. Therefore, these compounds can be used as candidate compounds for anti-tumor drugs.
  • One of the objectives of the present invention is to provide a 2-cyano-3,12-dioxooleanane-1,9(11)-diene-17-benzeneacrylamide compound represented by formula I:
  • R 1 , R 2 , and R 3 are each independently selected from the following substituents: H, C1-3 alkyl, alkoxy, halogen, cyano, and C1-3 alkyl substituted by halogen or cyano.
  • the halogen is selected from F, Cl, Br, I.
  • the alkoxy group is an alkoxy group containing 1 to 3 carbon atoms.
  • R 1 and R 2 in the above formula I are each independently selected from H or cyano; R 3 is selected from H, C1-3 alkyl, alkoxy or halogen.
  • R 1 and R 2 in the above formula I are each independently selected from H or cyano; R 3 is selected from F, Cl, H, methoxy.
  • R 1 and R 2 in the above formula I are each independently selected from H or cyano; R 3 is selected from Cl, H.
  • the R 1 in the above formula I is cyano, R 2 is H, and R 3 is Cl or H.
  • the present invention provides the following compound of formula I or a pharmaceutically acceptable salt thereof:
  • R 1 , R 2 , and R 3 are each independently selected from the following substituents: H, C1-6 alkyl, C1-6 alkoxy, halogen, cyano, C1-6 alkane substituted by halogen or cyano Group; preferably H, C1-3 alkyl, C1-3 alkoxy, halogen, cyano, C1-3 alkyl substituted by halogen or cyano.
  • R 1 and R 2 in the above formula I are each independently selected from H or cyano;
  • R 3 is selected from H, C1-3 alkyl, alkoxy, halogen, substituted by halogen C1-3 alkyl;
  • the alkoxy group is an alkoxy group containing 1-3 carbon atoms;
  • the halogen is selected from F, Cl, Br, I.
  • R 1 is H or cyano
  • R 2 is H or cyano
  • R 3 is selected from H, methyl, methoxy, trifluoromethyl, Cl or F .
  • R 1 is H or cyano
  • R 2 is H or cyano
  • R 3 is Cl, H or trifluoromethyl.
  • the compound of formula I is selected from the following compounds:
  • the present invention also provides a method for preparing the compound represented by formula I, which is characterized in that the steps are as follows: 1. Curtius rearrangement of CDDO to obtain the C-17 aminoated derivative (CDDO-NH 2 ), structure As shown in formula II:
  • the condensing agent is selected from dicyclohexylcarbodiimide, N,N-diisopropylcarbodiimide, 1-ethyl-(3-dimethylaminopropyl)carbodiimide, benzo One or more of triazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate or benzotriazol-1-yl-oxytripyrrolidine hexafluorophosphate;
  • the solvent can be selected from but not limited to N,N dimethylformamide, acetone, acetonitrile, toluene, benzene, xylene, 1,4-dioxane, ethyl acetate, dichloromethane, chloroform, tetrahydrofuran or ether
  • a further object of the present invention is to provide a pharmaceutical composition containing an effective dose of the compound of the present invention or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable pharmaceutical excipients.
  • the compound of the present invention can be made into different dosage forms alone or with one or more pharmaceutical carriers, such as tablets, capsules, granules, liquid preparations, etc., for clinical oral, injection or topical administration. In these different preparations, the content of the compound of the present invention can be 0.1% to 99.9%.
  • the dosage of the compound of the present invention can be 0.001-10000 mg/kg/0.3 days, which can be adjusted appropriately according to clinical needs.
  • the "pharmaceutically acceptable salt” in the present invention refers to a pharmaceutically acceptable acid or base addition salt, or a solvate thereof.
  • Another object of the present invention is to provide the use of such compounds or their pharmaceutically acceptable salts and their pharmaceutical compositions in the preparation of anti-tumor drugs.
  • the tumor is selected from lung cancer, liver cancer, colon cancer, pancreatic cancer, breast cancer, prostate cancer, brain cancer, ovarian cancer, cervical cancer, testicular cancer, kidney cancer, head and neck cancer, lymphoma, melanoma or leukemia. Further, the tumor is selected from lung cancer, liver cancer or breast cancer. Lung cancer is preferred.
  • a series of tumor cell test results show that the compound of the present invention has broad-spectrum anti-tumor activity, and its IC 50 values are in the nanomolar to micromolar level, which is equivalent to the activity of the positive control drug CDDO-Me.
  • the tumor is selected from lung cancer, liver cancer, ascites tumor, brain metastasis, colon cancer, pancreatic cancer, breast cancer, prostate cancer, brain cancer, ovarian cancer, cervical cancer, testicular cancer, kidney cancer, head and neck cancer, lymphoma, melanin Tumor or leukemia; preferably selected from lung cancer, liver cancer, breast cancer, ascites tumor, pancreatic cancer, brain metastases; more preferably selected from non-small cell lung cancer, liver cancer, breast cancer, ascites tumor.
  • a series of tumor cell test results show that the compound of the present invention has broad-spectrum anti-tumor activity, and its IC 50 values are in the nanomolar to micromolar level, which is equivalent to the activity of the positive control drug CDDO-Me.
  • the toxicity of compounds I-7 and I-12 to rat embryonic cardiomyocytes H9C2 was significantly lower than that of CDDO-Me (IC 50 of 0.308 ⁇ 0.01 ⁇ M) ;
  • the tumor is selected from the group consisting of lung cancer, liver cancer, ascites tumor, brain metastasis, colon cancer, pancreatic cancer, breast cancer, prostate cancer, brain cancer, ovarian cancer, cervical cancer, testicular cancer, kidney cancer, head and neck cancer, lymphoma , Melanoma or leukemia; preferably selected from lung cancer, liver cancer, breast cancer, ascites tumor, pancreatic cancer, brain metastases; more preferably selected from non-small cell lung cancer, liver cancer, breast cancer, ascites tumor.
  • a series of tumor cell test results show that the compound of the present invention has broad-spectrum anti-tumor activity, and its IC 50 values are in the nanomolar to micromolar level, which is equivalent to the activity of the positive control drug CDDO-Me.
  • the toxicity of compounds I-7 and I-12 to rat embryonic cardiomyocytes H9C2 was significantly lower than that of CDDO-Me (IC 50 of 0.308 ⁇ 0.01 ⁇ M) ;
  • Both I-16 and I-18 showed lower toxicity to human renal tubular epithelial cells HK-2.
  • Another object of the present invention is to provide a method for treating tumors, which comprises administering a therapeutically effective amount of the above-mentioned compound or a pharmaceutically acceptable salt and pharmaceutical composition thereof to a subject or patient.
  • the tumor is selected from the group consisting of lung cancer, liver cancer, ascites tumor, brain metastasis, colon cancer, pancreatic cancer, breast cancer, prostate cancer, brain cancer, ovarian cancer, cervical cancer, testicular cancer, kidney cancer, head and neck cancer, lymphoma , Melanoma or leukemia; preferably selected from lung cancer, liver cancer, breast cancer, ascites tumor, pancreatic cancer, brain metastases; more preferably selected from non-small cell lung cancer, liver cancer, breast cancer, ascites tumor.
  • a series of tumor cell test results show that the compound of the present invention has broad-spectrum anti-tumor activity, and its IC 50 values are in the nanomolar to micromolar level, which is equivalent to the activity of the positive control drug CDDO-Me.
  • the toxicity of compounds I-7 and I-12 to rat embryonic cardiomyocytes H9C2 was significantly lower than that of CDDO-Me (IC 50 of 0.308 ⁇ 0.01 ⁇ M) ;
  • Both I-16 and I-18 showed lower toxicity to human renal tubular epithelial cells HK-2.
  • the manufacturer's instructions for the use of the kit can be used, or the reaction and purification can be performed in a manner known in the art or the instructions of this application.
  • the above-mentioned techniques and methods can be implemented according to the descriptions in a number of summary and more specific documents cited and discussed in this specification according to conventional methods well known in the art.
  • groups and their substituents can be selected by those skilled in the art to provide stable structural parts and compounds.
  • substituent When a substituent is described by a conventional chemical formula written from left to right, the substituent also includes the chemically equivalent substituent obtained when the structural formula is written from right to left.
  • CH 2 O is equivalent to OCH 2 .
  • the "compounds" mentioned in this application include all stereoisomers, geometric isomers, tautomers and isotopes.
  • the compounds of the application may be asymmetric, for example, have one or more stereoisomers. Unless otherwise specified, all stereoisomers include, for example, enantiomers and diastereomers.
  • the compounds of the present application containing asymmetrically substituted carbon atoms can be isolated in an optically pure form or in a racemic form. The optically active pure form can be resolved from the racemic mixture or synthesized by using chiral raw materials or chiral reagents.
  • the compounds of the present application also include tautomeric forms.
  • the tautomeric form is derived from the exchange of a single bond with an adjacent double bond accompanied by the migration of a proton.
  • the compounds of this application also include all isotopic atoms, whether in intermediates or final compounds.
  • Isotopic atoms include atoms that have the same atomic number but different mass numbers.
  • isotopes of hydrogen include tritium and deuterium.
  • the compounds of the present application include compounds in which part of hydrogen or all hydrogen (H) is replaced by tritium (T) and/or deuterium (D); it also includes the replacement of part or all of 12 C by 13 C and/or 14 C Compounds; and other isotopes (such as N, O, P, S) between substitution compounds, such as 14 N and 15 N; 18 O and 17 O; 31 P and 32 P; 35 S and 36 S, etc.
  • the compounds described herein may have one or more stereoisomeric centers, and each isomeric center may exist in the form of R or S configuration or a combination thereof.
  • the compounds described herein may have one or more double bonds, and each double bond may exist in the E (trans) or Z (cis) configuration or a combination thereof.
  • a specific stereoisomer, structural isomer, diastereomer, enantiomer or epimer shall be understood to include all possible isomers, such as stereoisomers, structural Isomers, diastereomers, enantiomers or epimers and mixtures thereof. Therefore, the compounds described herein include all stereoisomers, structural isomers, diastereomers, enantiomers or epimeric forms that differ in configuration and their corresponding mixtures. Techniques for transforming specific stereoisomers or keeping specific stereoisomers intact, as well as techniques for resolving mixtures of stereoisomers are well known in the art, and those skilled in the art can choose suitable methods for specific situations
  • C 1 - 3 refer to the portion having 1-3 carbon atoms, i.e., the group contains 1 carbon atom, 2 carbon atoms, 3 carbon atoms. Therefore, for example, "C 1 -C 4 alkyl” refers to an alkyl group having 1 to 4 carbon atoms, that is, the alkyl group is selected from methyl, ethyl, propyl, isopropyl, n-butyl Group, isobutyl, sec-butyl and tert-butyl.
  • alkyl refers to an optionally substituted linear or optionally substituted branched aliphatic hydrocarbon.
  • the "alkyl” herein may preferably have 1 to about 20 carbon atoms, for example, 1 to about 10 carbon atoms, 1 to about 8 carbon atoms, or 1 to about 6 carbon atoms, or 1 to about 4 Carbon atoms or 1 to about 3 carbon atoms.
  • Examples of alkyl groups herein include, but are not limited to, methyl, ethyl, n-propyl, isopropyl and the like.
  • alkyl When a group as defined herein, such as “alkyl” appears numerical range, for example, “C 1 -C 6 alkyl” or “C 1 - 6 alkyl” refers to by a carbon atom, 2 carbon atoms, 3 An alkyl group composed of carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms. The alkyl group herein also includes the case where the numerical range is not specified.
  • alkyl used in combination herein includes an alkyl group combined with other groups, such as the alkyl group in an alkoxy group.
  • halogen used herein alone or in combination is selected from F, Cl, Br, and I.
  • halo or "halogen substituted” as used herein alone or in combination means that one or more hydrogen atoms of an optionally substituted group (such as alkyl, alkenyl, and alkynyl) are replaced with fluorine or chlorine. , Bromine, iodine atom or a combination thereof.
  • the same halogen atoms are used to replace two or more hydrogen atoms (for example, difluoromethyl, trifluoromethyl); in other embodiments, halogen atoms that are not exactly the same as each other are used to replace two Or multiple hydrogen atoms (e.g. 1-chloro-1-fluoro-1-iodoethyl).
  • Non-limiting examples of haloalkyl groups are fluoromethyl and bromoethyl.
  • a non-limiting example of haloalkenyl is bromovinyl.
  • a non-limiting example of haloalkynyl is chloroethynyl.
  • treatment and other similar synonyms include alleviating, alleviating or ameliorating the symptoms of a disease or condition, inhibiting the disease or condition, for example, preventing the development of the disease or condition, alleviating the disease or condition, making the disease or condition better, and relieving the disease or condition.
  • symptoms caused by a disease, or stop the symptoms of a disease or disease prevent other symptoms, ameliorate or prevent the underlying metabolic cause that causes the symptoms, and in addition, the term encompasses the purpose of prevention.
  • the term also includes obtaining therapeutic effects and/or preventive effects.
  • the therapeutic effect refers to curing or improving the underlying disease being treated.
  • the cure or improvement of one or more physiological symptoms related to the underlying disease is also a therapeutic effect, for example, although the patient may still be affected by the underlying disease, the patient's condition is observed to improve.
  • the composition can be administered to patients who are at risk of suffering from a specific disease, or even if a disease diagnosis has not been made, the composition can be administered to patients who have developed one or more physiological symptoms of the disease.
  • an "effective amount” for treatment refers to at least one active substance sufficient to relieve one or more symptoms of the disease or condition being treated after administration (such as the compound of this application). The result can be a reduction and/or alleviation of signs, symptoms or causes, or any other desired changes in the biological system.
  • an "effective amount” for treatment is the amount of the composition containing the compound disclosed herein that is required to provide significant disease relief clinically. Techniques such as dose escalation tests can be used to determine the effective amount suitable for any individual case.
  • pharmaceutically acceptable refers to a substance (such as a carrier or diluent) that does not affect the biological activity or properties of the compound of the application, and is relatively non-toxic, that is, the substance can be administered to an individual without causing adverse biological reactions Or interact with any component contained in the composition in an undesirable manner.
  • pharmaceutical composition refers to a mixture of the compound of the present application and at least one pharmaceutically acceptable substance.
  • pharmaceutically acceptable substances include, but are not limited to, carriers, stabilizers, diluents, dispersants, suspending agents, thickeners and/or excipients.
  • carrier refers to a relatively non-toxic substance that facilitates the introduction of the compound of the present application into cells or tissues.
  • pharmaceutically acceptable salt refers to a salt that retains the biological efficacy of the free acid and free base of the specified compound and has no adverse effects in biology or other aspects.
  • the compounds of the application also include pharmaceutically acceptable salts.
  • a pharmaceutically acceptable salt refers to a form in which the base group in the parent compound is converted into a salt form.
  • Pharmaceutically acceptable salts include, but are not limited to, inorganic or organic acid salts of base groups such as amine (amino) groups.
  • the pharmaceutically acceptable salt of the present application can be synthesized from the parent compound, that is, the basic group in the parent compound reacts with 1-4 equivalents of acid in a solvent system. Suitable salts are listed in Remingtong's Pharmaceutical Scicences, 17 th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977).
  • the salt in this application refers to the acid salt formed with organic acid/inorganic acid, and the basic salt formed with organic base/inorganic base.
  • the basic functional group of the compound of the general formula is pyridine or imidazole (but not limited to pyridine or imidazole)
  • the acidic functional group is carboxylic acid (but not limited to carboxylic acid)
  • zwitterions internal salts
  • the organic layer was washed with 5 mL saturated sodium chloride, and dried over anhydrous sodium sulfate. After suction filtration, the organic layer was spin-dried. After column chromatography, the organic layer was spin-dried to obtain 0.036 g of a yellow-white solid, with a yield of 44.9%.
  • Intermediate III-1 2-cyano-3-phenylacrylic acid, replace benzaldehyde with 4-trifluoromethylbenzaldehyde, and the other conditions remain unchanged.
  • Intermediate III-4 weighs 0.872g, yields The rate is 80.4%.
  • intermediate 2-cyano-3-phenylacrylic acid III-1 replace benzaldehyde with 4-fluorobenzaldehyde, and other conditions remain unchanged.
  • the intermediate III-5 weighs 0.683 g, and the yield is 79.4%. .
  • intermediate III-7 was used instead of 3-phenylacrylic acid as the reaction reagent, and other conditions remained unchanged.
  • the target compound I-13 was obtained as a pale yellowish white solid 0.030 g with a yield of 36.2%.
  • the intermediate III-8 was used instead of 3-phenylacrylic acid as the reaction reagent, and other conditions remained unchanged.
  • the target compound I-14 was obtained as a yellow-white solid 0.035 g with a yield of 40.7%.
  • the intermediate III-9 was used instead of 3-phenylacrylic acid as the reaction reagent, and other conditions remained unchanged.
  • the target compound I-15 was obtained as a light yellow-brown solid 0.031 g with a yield of 35.4%.
  • the anti-tumor activity of the compound of the present invention was tested by the tetramethylazole blue colorimetric method (MTT method), and bardoxolone methyl (CDDO-Me) was selected as the positive control drug.
  • MTT method tetramethylazole blue colorimetric method
  • CDDO-Me bardoxolone methyl
  • DMEM fetal bovine serum
  • SIGMA trypsin
  • SIGMA DMSO
  • Cell lines human non-small cell lung cancer cell line A549, human liver cancer cell line HepG2, human breast cancer cell line MCF-7, human renal tubular epithelial cell HK-2, rat embryonic cardiomyocyte H9C2 (all by Jiangsu Kaiji Biotechnology Co., Ltd. provided).
  • Method Resuscitate the frozen cell line and place it in a constant temperature 37°C CO 2 incubator. Change the medium once a day. When it is in the exponential growth phase, it can be plated. Add 1ml 0.25% trypsin digestion solution, digest for 1-2min, observe the cell status under the microscope, when the adherent cells become round and shrink, the digestion solution can be sucked out, add 1-2ml DMEM medium containing 10% fetal bovine serum Make a cell suspension, count the cells, calculate the amount of cell suspension required according to the number of 5 ⁇ 10 4 cells per well and the total number of wells, inoculate the cell suspension on a 96-well plate, 100 ⁇ l/well, around Seal with PBS and place in a constant temperature 37°C CO 2 incubator for 24 hours.
  • test drug The test drug, the positive control drug CDDO-Me, and the blank control group DMSO were prepared with DMEM medium to make the final concentration of 5 ⁇ M/well, 3 replicate holes for each drug, and culture for 48 hours.
  • Use an enzyme-linked immunoassay to detect the absorbance of each well at a wavelength of 570nm, and calculate the cell inhibition rate according to the following formula.
  • the average value of the 3 preliminary screening results is the final inhibition rate.
  • the compounds with the preliminary screening inhibition rate greater than 60% are screened by concentration gradient (5 times dilution) to prepare the IC 50 value of the tested drug (calculated by graphpad software), 3 times the experiment was repeated for the final results of the test compound IC 50 value.
  • Cell inhibition rate % [(OD value of blank control-OD value of administration group)/OD value of blank control group] ⁇ 100%
  • Table 1 The inhibitory activity of the representative compounds of the present invention on the proliferation of some tumor cells and cardiomyocytes (IC 50 , ⁇ M)
  • the inhibitory activity of most of the compounds of the present invention on cardiomyocyte H9C2 is greater than or comparable to CDDO-Me.
  • Compound I-1, I-2, I-3, I-4, I-5, I-6, I-7, I-8, I-9, I-12, I-13, I-14, I Both -16 and I-18 showed lower toxicity to human renal tubular epithelial cells HK-2.
  • the inhibitory activity of compounds I-7 and I-12 on normal cardiomyocytes H9C2 is relatively small (IC 50 values are 3.176 ⁇ 1.74 ⁇ M, 3.143 ⁇ 1.53 ⁇ M, respectively), which is approximately CDDO-Me (IC 50 is 0.308 ⁇ 0.01 ⁇ M) ), showing low myocardial toxicity.
  • Example 32 The inhibitory effect of the compound of the present invention on tumors in tumor-bearing mice
  • mice Eight animals were used as the normal group, and the remaining mice were modeled by the following method.
  • the model mice were divided into tumor-bearing model group, compound 1-7 5mg/kg group, compound 1-7 15mg/kg group, compound 1-125mg/kg group, compound 1-12 15mg/kg group, compound 1-16 5mg/kg group, compound 1-16 15mg/kg group, CDDO-Me 15mg/kg group.
  • Compound 1-7 The 5 mg/kg group was given 5 mg/kg of compound 1-7;
  • Compound 1-12 The 5 mg/kg group was given 5 mg/kg of compound 1-12;
  • CDDO-Me 15mg/kg group was given 15mg/kg compound CDDO-Me
  • the normal group and the model group were given an equal volume of 0.5% sodium carboxymethyl cellulose.
  • the administration was continued for 7 days, and the necropsy was performed on the second day after the last administration.
  • Detection indicators weight, spleen weight, tumor. Grind the spleen on ice, split the red, incubate FITC-CD11b, LY6C, LY6G antibodies for 15 minutes, and detect CD11b+LY6Chi+, CD11b+LY6G+ by upflow.
  • MDSC is a group of immature cells derived from the myeloid lineage. Under normal circumstances, they can differentiate into mature macrophages, granulocytes and dendritic cells. Under pathological conditions, they will aggregate and activate. In tumors, MDSC can inhibit T cell immune response and can interact with other immune cells to jointly promote the formation of an immunosuppressive state of tumor microenvironment. In addition, MDSC can also promote tumor proliferation and metastasis by destroying extracellular matrix, promoting angiogenesis and other non-immune pathways. Indoleamine 2, 3 dioxygenase 1 (IDO1) is one of the important functional markers of MDSC.
  • IDO1 Indoleamine 2, 3 dioxygenase 1
  • MDSC can catalyze the metabolism of tryptophan in the tumor microenvironment, leading to the release of soluble kynurenine and its downstream metabolites, and inducing Treg and Antigen-presenting cells are immune to tolerance, which leads to tumor immune escape.
  • the compound of the present invention can inhibit the expression of MDSC and can improve the tumor microenvironment, suggesting that it has a therapeutic effect on lung cancer, liver cancer, pancreatic cancer, breast cancer, ascites tumor, brain metastasis, etc.
  • Example 32 is a representative example of the target compound of the present invention, and is not a limitation of the present invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

涉及药物化学领域和药物治疗学领域，具体涉及一类2-氰基-3,12-二氧代齐墩果烷-1,9(11)-二烯-17-苯丙烯酰胺衍生物及其制备方法；还涉及该类新化合物在制备抗癌药物中的应用。

Description

一种齐墩果烷苯丙烯酰胺衍生物及其制备方法和用途 技术领域
本发明涉及药物化学领域和药物治疗学领域，内容包括一类2-氰基-3,12-二氧代齐墩果烷-1,9(11)-二烯-17-苯丙烯酰胺化合物及其制备方法；本发明还涉及该类新化合物在制备抗癌药物中的应用。
技术背景
齐墩果酸(oleanonic acid,OA)属于五环三萜类天然产物，在植物界分布极为广泛，是许多中药的有效成分，具有广泛的生物活性。基于OA的结构优化一直是天然药物化学研究的热点之一。
Figure PCTCN2020131887-appb-000001
CDDO及其衍生物(CDDOs)是迄今发现的抗肿瘤、抗炎活性最强的半合成OA衍生物。与单一靶点药物不同，CDDOs具有多功能、多靶点、作用于整个细胞信号通路的特点，能从多个环节发挥抗肿瘤作用，因此活性高、不易耐药是该类衍生物的优点。其中CDDO的甲酯衍生物(2-氰基-3,12-二氧代齐墩果烷-1,9(11)-二烯-28-酸甲酯，CDDO-Me)，商品名甲基巴多索隆(Bardoxolone Methyl)，于2006年开展治疗晚期实体瘤和恶性淋巴瘤的Ⅰ期临床试验(NCT00529438；NCT00508807)。此外，CDDO-Me在2008年被FDA批准进行II型糖尿病引起的慢性肾病(Chronic Kidney Disease,CUK)的治疗评价(NCT00664027)，遗憾的是，因心衰导致致死率高，2013年11月终止于III期临床研究。另据报道，该药于2014年由FDA批准用于肺动脉高压(孤儿药)的临床研究，现处于III期临床研究阶段(II期NCT02036970；III期NCT02657356)。
Figure PCTCN2020131887-appb-000002
尽管CDDO-Me具有良好的抗肿瘤活性，但其心肌毒性依然值得关注。若能通过必要的修饰改造，保留或增强该类化合物的活性，降低其毒性，将具有重要现实意义。
发明内容
本发明首次公开一类2-氰基-3,12-二氧代齐墩果烷-1,9(11)-二烯-17-苯丙烯酰胺化合物及其制备方法和医药用途。发明中该类衍生物的制备方法具有如下优点：原料廉价易得，试剂环保低毒，条件温和易控，后处理方便简单，同时还具有实用性和普适性。药理实验结果表明，本发明化合物具有优良的抗肿瘤活性，较CDDO-Me提高或相当；部分化合物的心肌毒性明显降低。因此，该类化合物可作为抗肿瘤药物的候选化合物。
本发明的目的之一在于提供式Ⅰ所示的2-氰基-3,12-二氧代齐墩果烷-1,9(11)-二烯-17-苯丙烯酰胺化合物：
Figure PCTCN2020131887-appb-000003
其中，R 1、R 2、R 3分别独立地选自以下取代基：H，C1-3烷基，烷氧基，卤素，氰基，被卤素或氰基取代的C1-3烷基。
所述的卤素选自F，Cl，Br，I。
所述烷氧基为含1-3个碳原子的烷氧基。
在一些实施方案中，上述式I中的所述R 1、R 2分别独立地选自H或氰基；R 3选自H，C1-3烷基，烷氧基或卤素。
在一些实施方案中，上述式I中的所述R 1、R 2分别独立地选自H或氰基；R 3选自F，Cl，H，甲氧基。
在一些实施方案中，上述式I中的所述R 1、R 2分别独立地选自H或氰基；R 3选自Cl，H。
在一些实施方案中，上述式I中的所述R 1为氰基，R 2为H，R 3为Cl或H。
另一方面，本发明提供了下述的式I化合物或其药学上可接受的盐：
Figure PCTCN2020131887-appb-000004
其中，R 1、R 2、R 3分别独立地选自以下取代基：H，C1-6烷基，C1-6烷氧基，卤素，氰基，被卤素或氰基取代的C1-6烷基；优选H，C1-3烷基，C1-3烷氧基，卤素，氰基，被卤素或氰基取代的C1-3烷基。
在一些实施方案中，上述式I中的所述R 1、R 2分别独立地选自H或氰基；R 3选自H，C1-3烷基，烷氧基，卤素，被卤素取代的C1-3烷基；所述烷氧基为含1-3个碳原子的烷氧基；所述卤素选自F，Cl，Br，I。
在一些实施方案中，上述式I中的所述R 1为H或氰基，R 2为H或氰基，R 3选自H、甲基、甲氧基、三氟甲基、Cl或F。
在一些实施方案中，上述式I中的所述R 1为H或氰基，R 2为H或氰基，R 3为Cl、H或三氟甲基。
在一些实施方案中，式Ⅰ化合物选自以下化合物：
Figure PCTCN2020131887-appb-000005
Figure PCTCN2020131887-appb-000006
本发明同时也提供了一种式Ⅰ所示化合物的制备方法，其特征是，步骤如下：1、将CDDO进行Curtius重排得到C-17位氨基化的衍生物(CDDO-NH 2)，结构如式Ⅱ所示：
Figure PCTCN2020131887-appb-000007
2、式Ⅱ与式Ⅲ(苯丙烯酸类化合物)经缩合反应制得式Ⅰ化合物：
Figure PCTCN2020131887-appb-000008
所述缩合剂选自二环己基碳二亚胺、N,N-二异丙基碳二亚胺、1-乙基-(3-二甲基氨基丙基)碳酰二亚胺、苯并三氮唑-1-基氧基三(二甲基氨基)磷鎓六氟磷酸盐或六氟磷酸苯并三唑-1-基-氧基三吡咯烷中的一种或多种；
溶剂可选自但不限于N,N二甲基甲酰胺、丙酮、乙腈、甲苯、苯、二甲苯、1,4-二氧六环、乙酸乙酯、二氯甲烷、氯仿、四氢呋喃或乙醚中的一种或多种；优选反应温度为0℃～60℃。
本发明的进一步目的在于提供一种含有有效剂量的本发明化合物或其药学上可接受的盐，和一种或多种药学上可接受的药用辅料制成的药物组合物。本发明化合物可单独或者与一种或一种以上药用载体制成不同剂型，例如片剂、胶囊剂、颗粒剂、液体制剂等，以供临床口服、注射或局部用药。在这些不同制剂中，本发明化合物的含量可以是0.1％-99.9％。本发明化合物的给药量可以是0.001-10000mg/kg/0.3天，根据临床需要可以适度调整。
本发明所述的“药学上可接受的盐”是指药学上可接受的酸或碱加成盐，或其溶剂化物。
本发明的另一目的在于提供该类化合物或其药学上可接受的盐及其药物组合物在制备抗肿瘤药物中的应用。所述肿瘤选自肺癌、肝癌、结肠癌、胰腺癌、乳腺癌、前列腺癌、脑癌、卵巢癌、宫颈癌、睾丸癌、肾癌、头颈癌、淋巴癌、黑色素瘤或白血病。进一步的，所述肿瘤选自肺癌、肝癌或乳腺癌。优选肺癌。一系列肿瘤细胞测试结果表明，本发明的化合物具有广谱抗肿瘤活性，其IC 50值均处于纳摩尔至微摩尔级，与阳性对照药CDDO-Me活性相当。其中，化合物I-7和I-12对大鼠胚胎心肌细胞H9C2的毒性(IC 50值分别为3.176±1.74μM，3.143±1.53μM)明显低于CDDO-Me(IC 50为0.308±0.01μM)。
本发明的另一目的在于提供该类化合物或其药学上可接受的盐及其药物组合物在制备抗肿瘤药物中的应用。所述肿瘤选自肺癌、肝癌、腹水瘤、脑转移瘤、结肠癌、胰腺癌、乳腺癌、前列腺癌、脑癌、卵巢癌、宫颈癌、睾丸癌、肾癌、头颈癌、淋巴癌、黑色素瘤或白血病；优选选自肺癌、肝癌、乳腺癌、腹水瘤、胰腺癌、脑转移瘤；更优选选自非小细胞肺癌、肝癌、乳腺癌、腹水瘤。一系列肿瘤细胞测试结果表明，本发明的化合物具有广谱抗肿瘤活性，其IC 50值均处于纳摩尔至微摩尔级，与阳性对照药CDDO-Me活性相当。其中，化合物I-7和I-12对大鼠胚胎心肌细胞H9C2的毒性(IC 50值分别为3.176±1.74μM，3.143±1.53μM)明显低于CDDO-Me(IC 50为0.308±0.01μM)；另外，化合物I-1、I-2、I-3、I-4、I-5、I-6、I-7、I-8、I-9、I-12、I-13、I-14、I-16、I-18均表现出了对人肾小管上皮细胞HK-2更低的毒性。本发明的再另一目的在于提供该类化合物或其药学上可接受的盐及其药物组合物，其用于抗肿瘤。所述肿瘤选自选自肺癌、肝癌、腹水瘤、脑转移瘤、结肠癌、胰腺癌、乳腺癌、前列腺癌、脑癌、卵巢癌、宫颈癌、睾丸癌、肾癌、头颈癌、淋巴癌、黑色素瘤或白血病；优选选自肺癌、肝癌、乳腺癌、腹水瘤、胰腺癌、脑转移瘤；更优选选自非小细胞肺癌、肝癌、乳腺癌、腹水瘤。一系列肿瘤细胞测试结果表明，本发明的化合物具有广谱抗肿瘤活性，其IC 50值均处于纳摩尔至微摩尔级，与阳性对照药CDDO-Me活性相当。其中，化合物I-7和I-12对大鼠胚胎心肌细胞H9C2的毒性(IC 50值分别为3.176±1.74μM，3.143±1.53μM)明显低于CDDO-Me(IC 50为0.308±0.01μM)；另外，化合物I-1、I-2、I-3、I-4、I-5、I-6、I-7、I-8、I-9、I-12、I-13、I-14、I-16、I-18均表现出了对人肾小管上皮细胞HK-2更低的毒性。
本发明的再另外的目的在于提供一种治疗肿瘤的方法，包括将治疗有效量的上述的该类化合物或其药学上可接受的盐及其药物组合物施用于受试者或患者。所述肿瘤选自选自肺癌、肝癌、腹水瘤、脑转移瘤、结肠癌、胰腺癌、乳腺癌、前列腺癌、脑癌、卵巢癌、宫颈癌、睾丸癌、肾癌、头颈癌、淋巴癌、黑色素瘤或白血病；优选选自肺癌、肝癌、乳腺癌、腹水瘤、胰腺癌、脑转移瘤；更优选选自非小细胞肺癌、肝癌、乳腺癌、腹水瘤。一系列肿瘤细胞测试结果表明，本发明的化合物具有广谱抗肿瘤活性，其IC 50值均处于纳摩尔至微摩尔级，与阳性对照药CDDO-Me活性相当。其中，化合物I-7和I-12对大鼠胚胎心肌细胞H9C2的毒性(IC 50值分别为3.176±1.74μM，3.143±1.53μM)明显低于CDDO-Me(IC 50为0.308±0.01μM)；另外，化合物I-1、I-2、I-3、I-4、I-5、I-6、I-7、I-8、I-9、I-12、I-13、I-14、I-16、I-18均表现出了对人肾小管上皮细胞HK-2更低的毒性。
虽然本文已经显示和描述了本发明的优选实施方案，但对本领域技术人员显而易见的是，此类实施方案仅通过举例的方式提供。现在，本领域技术人员会想到不背离本发明的许多改变、变化和替代。应理解的是，对本发明所述的本发明实施方案的各种替代可用于实施本发明。所附权利要求旨在限定本发明范围，并且由此覆盖了在这些权利要求范围内的方法和结构及其等同形式。
某些化学术语
除非另有定义，否则本文所有科技术语具有的涵义与权利要求主题所属领域技术人员通常理解的涵义相同。除非另有说明，本文全文引用的所有专利、专利申请、公开材料通过引用方式整体并入本文。
应理解，上述简述和下文的详述为示例性且仅用于解释，而不对本申请主题作任何限制。 在本申请中，除非另有具体说明，否则使用单数时也包括复数。还应注意，除非另有说明，否则所用“或”、“或者”表示“和/或”。此外，所用术语“包括”以及其它形式，例如“包含”、“含”和“含有”都属非限制性描述。
可在参考文献(包括Carey and Sundberg"ADVANCED ORGANIC CHEMISTRY 4 TH ED."Vols.A(2000)and B(2001),Plenum Press,New York)中找到对标准化学术语的定义。除非另有说明，否则采用本领域技术范围内的常规方法，如质谱、NMR、IR和UV/Vis光谱法和药理学方法。除非提出具体定义，否则本文在分析化学、有机合成化学以及药物和药物化学的有关描述中采用的术语是本领域已知的。可在化学合成、化学分析、药物制备、制剂和递送，以及对患者的治疗中使用标准技术。例如，可利用厂商对试剂盒的使用说明，或者按照本领域公知的方式或本申请的说明来实施反应和进行纯化。通常可根据本说明书中引用和讨论的多个概要性和较具体的文献中的描述，按照本领域熟知的常规方法实施上述技术和方法。在本说明书中，可由本领域技术人员选择基团及其取代基以提供稳定的结构部分和化合物。
当通过从左向右书写的常规化学式描述取代基时，该取代基也同样包括从右向左书写结构式时所得到的在化学上等同的取代基。举例而言，CH 2O等同于OCH 2。
本申请所述的“化合物”是指包括所有立体异构体、几何异构体、互变异构体和同位素。本申请化合物可以是不对称的，例如，具有一个或多个立体异构体。除非另有说明，所有立体异构体都包括，如对映异构体和非对映异构体。本申请的含有不对称取代碳原子的化合物可以以光学活性纯的形式或外消旋形式被分离出来。光学活性纯的形式可以从外消旋混合物拆分，或通过使用手性原料或手性试剂合成。本申请化合物还包括互变异构体形式。互变异构体形式来源于一个单键与相邻的双键交换并一起伴随一个质子的迁移。本申请的化合物还包括所有同位素的原子，无论是在中间体或最后的化合物。同位素的原子包括具有相同的原子数，但不同质量数。例如，氢的同位素包括氚和氘。也就是说，本申请的化合物包括部分氢或全部氢(H)被氚(T)和/或氘(D)所替代的化合物；还包括部分或全部 12C被 13C和/或 14C替代的化合物；以及其他同位素(如N,O,P,S)之间替代的化合物,如 14N与 15N； 18O与 17O； 31P与 32P； 35S与 36S等。本文所述化合物可具有一个或多个立体异构中心，且各个异构中心可以以R或S构型或其组合的形式存在。类似地，本文所述化合物可具有一个或多个双键，且各双键可以以E(反式)或Z(顺式)构型或其组合的形式存在。一个特定的立体异构体、结构异构体、非对映异构体、对映异构体或差向异构体应被理解为包括所有可能的异构体，如立体异构体、结构异构体、非对映异构体、对映异构体或差向异构体及其混合物。因此，本文所述化合物包括所有构型上不同的立体异构体、结构异构体、非对映异构体、对映异构体或差向异构体形式以及其相应的混合物。用于转化特定立体异构体或使特定立体异构体保持原状的技术，以及拆分立体异构体混合物的技术是本领域熟知的，本领域技术人员能够就具体情况选择适合的方法
术语“任选/任意”或“任选地/任意地”是指随后描述的事件或情况可能发生或可能不发生，该描述包括发生所述事件或情况和不发生所述事件或情况。
本文所用C 1- 3是指该部分中具有1-3个碳原子，即基团包含1个碳原子，2个碳原子、3个碳原子。因此，举例而言“C 1-C 4烷基”是指在有1-4个碳原子的烷基，即所述烷基选自甲基、乙基、丙基、异丙基、正丁基、异丁基、仲丁基和叔丁基。
本文单独或组合使用的术语“烷基”是指任选取代的直链或任选取代的支链的脂肪族烃类。本文的“烷基”优选可具有1-约20个碳原子，例如具有1-约10个碳原子，具有1-约8个碳原子，或1-约6个碳原子，或1-约4个碳原子或1-约3个碳原子。本文的烷基实施例包括但不限于甲基、乙基、正丙基、异丙基等。本文定义的基团，如“烷基”出现数字范围时，例如“C 1-C 6烷基”或“C 1- 6烷基”是指可由1个碳原子、2个碳原子、3个碳原子、4个碳原子、5个碳原子或6个碳原子构成的烷基，本文的烷基也包含未指定数字范围的情况。
本文组合使用的“烷基”包括与其他基团结合的烷基，例如烷氧基中的烷基。
本文单独或组合使用的术语“卤素”选自F，Cl，Br，I。
本文单独或组合使用的术语“卤代”或“卤素取代”是指任选被取代的基团(如烷基、烯基和炔基)的其中一个或多个氢原子被替换成氟、氯、溴、碘原子或其组合。在一些实施方式中，使用彼此相同的卤素原子替换两个或多个氢原子(例如二氟甲基、三氟甲基)；在其它实施方式中使用彼此并不完全相同的卤素原子替换两个或多个氢原子(例如1-氯-1-氟-1-碘乙基)。卤代烷基的非限定性实施例为氟甲基和溴乙基。卤代烯基的非限定性实施例为溴乙烯基。卤代炔基的非限定性实施例为氯乙炔基。
本文所用的术语“治疗”和其它类似的同义词包括缓解、减轻或改善疾病或病症症状，抑制疾病或病症，例如阻止疾病或病症的发展，缓解疾病或病症，使疾病或病症好转，缓解由疾病或病症导致的症状，或者中止疾病或病症的症状，预防其它症状，改善或预防导致症状的潜在代谢原因，此外，该术语包含预防的目的。该术语还包括获得治疗效果和/或预防效果。所述治疗效果是指治愈或改善所治疗的潜在疾病。此外，对与潜在疾病相关的一种或多种生理症状的治愈或改善也是治疗效果，例如尽管患者可能仍然受到潜在疾病的影响，但观察到患者情况改善。就预防效果而言，可向具有患特定疾病风险的患者施用所述组合物，或者即便尚未做出疾病诊断，但向出现该疾病的一个或多个生理症状的患者施用所述组合物。
本文所使用术语“有效量”、“治疗有效量”或“药学有效量”是指服用后足以在某种程度上缓解所治疗的疾病或病症的一个或多个症状的至少一种活性物质(如本申请的化合物)的量。其结果可以为迹象、症状或病因的消减和/或缓解，或生物系统的任何其它所需变化。例如，用于治疗的“有效量”是在临床上提供显著的病症缓解效果所需的包含本文公开化合物的组合物的量。可使用诸如剂量递增试验的技术测定适合于任意个体病例中的有效量。
本文针对制剂、组合物或成分所用术语“可接受的”是指对接受治疗的受试者的一般健康情况没有长期的有害影响。
本文所用术语“药学可接受的”是指不影响本申请化合物的生物活性或性质的物质(如载体或稀释剂)，并且相对无毒，即该物质可施用于个体而不造成不良的生物反应或以不良方式与组合物中包含的任意组分相互作用。
本文所用术语“药物组合物”是指本申请的化合物与至少一种药学可接受的物质相混的混合物。所述药学可接受的物质包括但不限于载体、稳定剂、稀释剂、分散剂、悬浮剂、增稠剂和/或赋形剂。
本文所用术语“载体”是指相对无毒的物质，其有助于将本申请的化合物引入到细胞或组织中。
本文所用术语“药学可接受的盐”是指保留了指定化合物的游离酸和游离碱的生物效力，并且在生物学或其它方面上没有不良作用的盐。本申请化合物还包括药学可以接受的盐。药学可接受的盐是指把母体化合物中的碱基基团转换成盐的形式。药学可接受的盐包括，但不仅限于，碱基基团例如胺(氨)基的无机或有机酸盐类。本申请药学可接受的盐可以由母体化合物合成，即母体化合物中的碱性基团与1-4当量的酸在一个溶剂系统中反应。合适的盐列举在Remingtong’s Pharmaceutical Scicences,17 th ed.,Mack Publishing Company,Easton,Pa.,1985,p.1418和Journal of Pharmaceutical Science,66,2(1977)中。
除特别指示外，本申请中的盐指用有机酸/无机酸形成的酸式盐，以及用有机碱/无机碱形成的碱式盐。另外，当通式化合物的碱性官能团是吡啶或咪唑(但不限制于吡啶或咪唑)，酸性官能团是羧酸(但不限制于羧酸)时就会形成两性离子(内盐)，内盐也包括在本申请中的盐内。
具体实施方式
为了更清晰阐述本发明，在此列举一系列的实施例。这些实施例是例证性的，不应当理解为对本发明的限制。
实施例1：I-1的合成
将0.080g(0.170mmol)CDDO-NH 2溶于5mL二氯甲烷，加入0.046g(0.260mmol)3-苯基丙烯酸，搅拌，加入六氟磷酸苯并三唑-1-基-氧基三吡咯烷0.177g(PyBop，0.340mmol)， N，N-二异丙基乙胺0.074mL(0.425mmol)，室温下反应12h。TCL检测反应结束后，加入5mL水、5mL二氯甲烷，萃取分离，水层再用5mL二氯甲烷萃取，合并有机层。有机层用5mL饱和氯化钠洗，无水硫酸钠干燥。抽滤后旋干有机层，柱层析后旋干得黄白色固体0.036g，产率44.9％。
ESI-MS：593.4[M+H] +。
1H-NMR(300MHz,CDCl 3,TMS),δppm:0.89(3H,s),1.04(3H,s),1.05(3H,s),1.17(3H,s),1.26(3H,s),1.42(3H,s),1.47(3H,s),6.01(1H,s),6.53(1H,d,J＝15.60Hz),7.35(3H,m),7.48(2H,m),7.60(1H,d,J＝15.54Hz),8.08(1H,s).
Figure PCTCN2020131887-appb-000009
实施例2：I-2的合成
参照化合物I-1的制备方法，用3-(4-甲基苯基)丙烯酸替代3-苯基丙烯酸作为反应试剂，其他条件未变，制得目标化合物I-2淡黄色固体0.024g，产率28.8％。
ESI-MS：607.4[M+H] +。
1H-NMR(300MHz,CDCl 3,TMS),δppm:0.90(3H,s),1.05(6H,s),1.17(3H,s),1.27(3H,s),1.41(3H,s),1.47(3H,s),2.36(3H,s),6.01(1H,s),6.43(1H,d,J＝12.60Hz),7.19(2H,s),7.38(2H,s),7.57(1H,d,J＝15.27Hz),8.06(1H,s).
Figure PCTCN2020131887-appb-000010
实施例3：I-3的合成
参照化合物I-1的制备方法，用3-(4-甲氧基苯基)丙烯酸替代3-苯基丙烯酸作为反应试剂，其他条件未变，制得目标化合物I-3黄白色固体0.035g，产率41.2％。
ESI-MS：623.4[M+H] +,645.4[M+Na] +。
1H-NMR(300MHz,CDCl 3,TMS),δppm:0.92(3H,s),1.06(6H,s),1.18(3H,s),1.27(3H,s),1.42(3H,s),1.48(3H,s),3.84(3H,s),6.01(1H,s),6.90(1H,d,J＝8.49Hz),7.45(1H,d,J＝8.43Hz),7.58(4H,m),8.05(1H,s).
Figure PCTCN2020131887-appb-000011
实施例4：I-4的合成
参照化合物I-1的制备方法，用3-(4-三氟甲基甲基苯基)丙烯酸替代3-苯基丙烯酸作为反应试剂，其他条件未变，制得目标化合物I-4淡黄色固体0.018g，产率20.4％。
ESI-MS：661.4[M+H] +,683.4[M+Na] +。
1H-NMR(300MHz,CDCl 3,TMS),δppm:0.91(3H,s),1.06(3H,s),1.07(3H,s),1.18(3H,s),1.27(3H,s),1.44(3H,s),1.49(3H,s),6.03(1H,s),6.54(1H,d,J＝15.30Hz),7.61(4H,m),7.63(1H,d,J＝12.96Hz),8.09(1H,s).
Figure PCTCN2020131887-appb-000012
实施例5：I-5的合成
参照化合物I-1的制备方法，用3-(4-氟苯基)丙烯酸替代3-苯基丙烯酸作为反应试剂，其他条件未变，制得目标化合物I-5浅黄色固体0.019g，产率23.4％。
ESI-MS：611.4[M+H] +。
1H-NMR(300MHz,CDCl 3,TMS),δppm:0.89(3H,s),1.05(3H,s),1.06(3H,s),1.17(3H,s),1.26(3H,s),1.45(3H,s),1.49(3H,s),6.01(1H,s),6.55(1H,d,J＝8.58Hz),7.59(2H,s),7.64(2H,s),7.63(1H,d,J＝8.61Hz),8.09(1H,s).
Figure PCTCN2020131887-appb-000013
实施例6：I-6的合成
参照化合物I-1的制备方法，用3-(4-氯苯基)丙烯酸替代3-苯基丙烯酸作为反应试剂，其他条件未变，制得目标化合物I-6黄白色固体0.025g，产率29.1％。
ESI-MS：627.3[M+H] +。
1H-NMR(300MHz,CDCl 3,TMS),δppm:0.90(3H,s),1.05(3H,s),1.06(3H,s),1.18(3H,s),1.27(3H,s),1.44(3H,s),1.49(3H,s),6.03(1H,s),6.53(1H,d,J＝8.66Hz),7.62(2H,s),7.68(2H,s),7.61(1H,d,J＝8.64Hz),8.09(1H,s).
Figure PCTCN2020131887-appb-000014
实施例7：中间体Ⅲ-1 2-氰基-3-苯基丙烯酸的合成
用20mL甲苯溶解0.425g(5mmol)腈乙酸、0.477g(4.5mmol)苯甲醛，加入0.058g(0.75mmol)乙酸铵，加热回流，反应6-7h，由TCL检验反应完全。冷却至室温后，抽滤，滤饼真空干燥，得中间体Ⅲ-1，白色固体0.643g，产率82.4％。
ESI-MS：174.0[M+H] +。
反应式如下：
Figure PCTCN2020131887-appb-000015
实施例8：I-7的合成
参照化合物I-1的制备方法，用2-氰基-3-苯基丙烯酸替代3-苯基丙烯酸作为反应试剂，其他条件未变，制得目标化合物I-7浅黄色固体0.026g，产率30.7％。
ESI-MS：618.4[M+H] +,640.4[M+Na] +,616.4[M-H] -。
1H-NMR(300MHz,CDCl 3,TMS),δppm:0.93(3H,s),1.06(3H,s),1.13(3H,s),1.18(3H,s),1.27(3H,s),1.34(3H,s),1.49(3H,s),6.01(1H,s),7.35(3H,m),7.48(2H,m),8.06(1H,s),8.21(1H,s).
Figure PCTCN2020131887-appb-000016
实施例9：中间体Ⅲ-2 2-氰基-3-(4-甲基苯基)丙烯酸的合成
参照中间体2-氰基-3-苯基丙烯酸Ⅲ-1的合成方法，以4-甲基苯甲醛代替苯甲醛，其余条件不变，制得中间体Ⅲ-2重0.727g，产率86.3％。
ESI-MS：188.0[M+H] +。
反应式如下：
Figure PCTCN2020131887-appb-000017
实施例10：I-8的合成
参照化合物I-1的制备方法，用2-氰基-3-(4-甲基苯基)丙烯酸替代3-苯基丙烯酸作为反应试剂，其他条件未变，制得目标化合物I-8淡黄色固体0.031g，产率35.9％。
ESI-MS：632.4[M+H] +,654.4[M+Na] +,630.4[M-H] -。
1H-NMR(300MHz,CDCl 3,TMS),δppm:0.93(3H,s),1.06(3H,s),1.13(3H,s),1.18(3H,s),1.27(3H,s),1.34(3H,s),1.49(3H,s),2.43(3H,s),6.01(1H,s),6.99(2H,d,J＝8.48Hz),7.92(2H,d,J＝8.61Hz),8.06(1H,s),8.21(1H,s).
Figure PCTCN2020131887-appb-000018
实施例11：中间体Ⅲ-3 2-氰基-3-(4-甲氧基苯基)丙烯酸的合成
参照中间体Ⅲ-1 2-氰基-3-苯基丙烯酸的合成方法，以4-甲氧基苯甲醛代替苯甲醛，其余条件不变，制得中间体Ⅲ-3重0.794g，产率86.8％。
ESI-MS：204.0[M+H] +。
反应式如下：
Figure PCTCN2020131887-appb-000019
实施例12：I-9的合成
参照化合物I-1的制备方法，用2-氰基-3-(4-甲氧基苯基)丙烯酸替代3-苯基丙烯酸作为反 应试剂，其他条件未变，制得目标化合物I-9黄色固体0.030g，产率33.7％。
ESI-MS：648.4[M+H] +,670.4[M+Na] +。
1H-NMR(300MHz,CDCl 3,TMS),δppm:0.93(3H,s),1.06(3H,s),1.12(3H,s),1.17(3H,s),1.27(3H,s),1.34(3H,s),1.49(3H,s),3.11(3H,s),6.01(1H,s),6.99(2H,d,J＝8.49Hz),7.92(2H,d,J＝8.67Hz),8.06(1H,s),8.21(1H,s).
Figure PCTCN2020131887-appb-000020
实施例13：中间体Ⅲ-4 2-氰基-3-(4-三氟甲基苯基)丙烯酸的合成
参照中间体Ⅲ-1 2-氰基-3-苯基丙烯酸的合成方法，以4-三氟甲基苯甲醛代替苯甲醛，其余条件不变，制得中间体Ⅲ-4重0.872g，产率80.4％。
ESI-MS：242.0[M+H] +。
反应式如下：
Figure PCTCN2020131887-appb-000021
实施例14：I-10的合成
参照化合物I-1的制备方法，用2-氰基-3-(4-三氟甲基苯基)丙烯酸替代3-苯基丙烯酸作为反应试剂，其他条件未变，制得目标化合物I-10白色固体0.031g，产率32.9％。
ESI-MS：686.4[M+H] +,684.4[M-H] -。
1H-NMR(300MHz,CDCl 3,TMS),δppm:0.91(3H,s),1.02(3H,s),1.08(3H,s),1.17(3H,s),1.27(3H,s),1.44(3H,s),1.50(3H,s),6.05(1H,s),7.68(2H,d,J＝8.07Hz),7.88(2H,d,J＝8.01Hz),8.09(1H,s).
Figure PCTCN2020131887-appb-000022
实施例15：中间体Ⅲ-5 2-氰基-3-(4-氟苯基)丙烯酸的合成
参照中间体2-氰基-3-苯基丙烯酸Ⅲ-1的合成方法，以4-氟苯甲醛代替苯甲醛，其余条件不变，制得中间体Ⅲ-5重0.683g，产率79.4％。
ESI-MS：192.0[M+H] +。
反应式如下：
Figure PCTCN2020131887-appb-000023
实施例16：I-11的合成
参照化合物I-1的制备方法，用2-氰基-3-(4-氟苯基)丙烯酸替代3-苯基丙烯酸作为反应试剂，其他条件未变，制得目标化合物I-11淡黄色固体0.022g，产率25.4％。
ESI-MS：636.4[M+H] +,658.4[M+Na] +,635.4[M-H] -。
1H-NMR(300MHz,CDCl 3,TMS),δppm:0.94(3H,s),1.07(3H,s),1.13(3H,s),1.18(3H,s),1.27(3H,s),1.44(3H,s),1.50(3H,s),6.05(1H,s),7.21(4H,m),8.06(1H,s),8.26(1H,s).
Figure PCTCN2020131887-appb-000024
实施例17：中间体Ⅲ-6 2-氰基-3-(4-氯苯基)丙烯酸的合成
参照中间体2-氰基-3-苯基丙烯酸Ⅲ-1的合成方法，以4-氯苯甲醛代替苯甲醛，其余条件不变，制得中间体Ⅲ-6重0.712g，产率76.2％。
ESI-MS：208.0[M+H] +。
反应式如下：
Figure PCTCN2020131887-appb-000025
实施例18：I-12的合成
参照化合物I-1的制备方法，用2-氰基-3-(4-氯苯基)丙烯酸替代3-苯基丙烯酸作为反应试剂，其他条件未变，制得目标化合物I-12黄白色固体0.033g，产率37.9％。
ESI-MS：652.3[M+H] +,674.3[M+Na] +,650.3[M-H] -。
1H-NMR(300MHz,CDCl 3,TMS),δppm:0.92(3H,s),1.02(3H,s),1.08(3H,s),1.17(3H,s),1.27(3H,s),1.44(3H,s),1.50(3H,s),6.05(1H,s),7.42(2H,d,J＝8.47Hz),7.82(2H,d,J＝8.51Hz),8.12(1H,s).
Figure PCTCN2020131887-appb-000026
实施例19：中间体Ⅲ-7 3-氰基-3-苯基丙烯酸的合成
将0.735g(5mmol)苯乙腈溶于50mL甲醇，加入0.464g(5mmol)乙醛酸，投入1.035g(7.5mmol)碳酸钾，加热回流，以TCL结果指示反应终点。抽滤后，用二氯甲烷洗涤滤饼，将滤饼溶于水中，加入稀盐酸调至pH＝4，有白色固体析出。用乙酸乙酯(30mL×2)萃取，合并有机层，无水硫酸钠干燥。抽滤后，旋干，恒温干燥箱干燥，得中间体Ⅲ-7白色固体0.679g，产率达78.5％。
ESI-MS：174.0[M+H] +。
反应式如下：
Figure PCTCN2020131887-appb-000027
实施例20：I-13的合成
参照化合物I-1的制备方法，用中间体Ⅲ-7替代3-苯基丙烯酸作为反应试剂，其他条件未变，制得目标化合物I-13浅黄白色固体0.030g，产率36.2％。
ESI-MS：618.4[M+H] +,640.4[M+Na] +。
1H-NMR(300MHz,CDCl 3,TMS),δppm:0.91(3H,s),1.04(3H,s),1.06(3H,s),1.18(3H,s),1.34(3H,s),1.42(3H,s),1.47(3H,s),6.00(1H,s),7.03(1H,s),7.47(2H,m),7.69(3H,m),8.04(1H,s).
Figure PCTCN2020131887-appb-000028
实施例21：中间体Ⅲ-8 3-氰基-3-(4-甲基苯基)丙烯酸的合成
参照中间体3-氰基-3-苯基丙烯酸Ⅲ-7的合成方法，采用4-甲基苯乙腈代替苯乙腈作为反应试剂，其他条件不变，中间体Ⅲ-8制得0.733g，产率78.2％。
ESI-MS：188.0[M+H] +。
反应式如下：
Figure PCTCN2020131887-appb-000029
实施例22：I-14的合成
参照化合物I-1的制备方法，用中间体Ⅲ-8替代3-苯基丙烯酸作为反应试剂，其他条件未变，制得目标化合物I-14黄白色固体0.035g，产率40.7％。
ESI-MS：632.4[M+H] +,654.4[M+Na] +。
1H-NMR(300MHz,CDCl 3,TMS),δppm:0.90(3H,s),1.03(3H,s),1.06(3H,s),1.18(3H,s),1.27(3H,s),1.42(3H,s),1.47(3H,s),2.40(3H,s),6.00(1H,s),7.01(1H,s),7.26(2H,d,J＝8.16Hz),7.68(2H,d,J＝7.7Hz),8.04(1H,s).
Figure PCTCN2020131887-appb-000030
实施例23：中间体Ⅲ-9 3-氰基-3-(4-甲氧基苯基)丙烯酸的合成
参照中间体3-氰基-3-苯基丙烯酸Ⅲ-7的合成方法，采用4-甲氧基苯乙腈代替苯乙腈作为反应试剂，其他条件不变，中间体Ⅲ-9制得0.757g，产率74.5％。
ESI-MS：204.0[M+H] +。
反应式如下：
Figure PCTCN2020131887-appb-000031
实施例24：I-15的合成
参照化合物I-1的制备方法，用中间体Ⅲ-9替代3-苯基丙烯酸作为反应试剂，其他条件未变，制得目标化合物I-15浅黄褐色固体0.031g，产率35.4％。
ESI-MS：648.4[M+H] +,670.4[M+Na] +。
1H-NMR(300MHz,CDCl 3,TMS),δppm:0.89(3H,s),0.99(3H,s),1.04(3H,s),1.17(3H, s),1.27(3H,s),1.40(3H,s),1.45(3H,s),3.85(3H,s),6.00(1H,s),6.94(2H,d,J＝8.76Hz),7.03(1H,s),7.65(2H,d,J＝8.85Hz),8.06(1H,s).
Figure PCTCN2020131887-appb-000032
实施例25：中间体Ⅲ-10 3-氰基-3-(4-三氟甲基苯基)丙烯酸的合成
参照中间体3-氰基-3-苯基丙烯酸Ⅲ-7的合成方法，采用4-三氟甲基苯乙腈代替苯乙腈作为反应试剂，其他条件不变，中间体Ⅲ-10制得0.833g，产率69.1％。
ESI-MS：242.0[M+H] +。
反应式如下：
Figure PCTCN2020131887-appb-000033
实施例26：I-16的合成
参照化合物I-1的制备方法，用中间体Ⅲ-10替代3-苯基丙烯酸作为反应试剂，其他条件未变，制得目标化合物I-16浅黄褐色固体0.056g，产率60.2％。
ESI-MS：686.4[M+H] +,708.4[M+Na] +。
1H-NMR(300MHz,CDCl 3,TMS),δppm:0.89(3H,s),1.00(3H,s),1.06(3H,s),1.18(3H,s),1.28(3H,s),1.42(3H,s),1.47(3H,s),6.04(1H,s),7.15(1H,s),7.73(2H,d,J＝8.13Hz),7.82(2H,d,J＝7.89Hz),8.09(1H,s).
Figure PCTCN2020131887-appb-000034
实施例27：中间体Ⅲ-11 3-氰基-3-(4-氟苯基)丙烯酸的合成
参照中间体3-氰基-3-苯基丙烯酸Ⅲ-7的合成方法，采用4-氟苯乙腈代替苯乙腈作为反应试剂，其他条件不变，中间体Ⅲ-11制得0.956g，产率81.9％。
ESI-MS：192.0[M+H] +。
反应式如下：
Figure PCTCN2020131887-appb-000035
实施例28：I-17的合成
参照化合物I-1的制备方法，用中间体Ⅲ-11替代3-苯基丙烯酸作为反应试剂，其他条件未变，制得目标化合物I-17黄白色固体0.023g，产率27.0％。
ESI-MS：636.4[M+H] +,658.4[M+Na] +。
1H-NMR(300MHz,CDCl 3,TMS),δppm:0.90(3H,s),1.01(3H,s),1.06(3H,s),1.18(3H,s),1.34(3H,s),1.43(3H,s),1.49(3H,s),6.04(1H,s),6.96(1H,s),7.15(2H,d,J＝8.49Hz),7.70(2H,d,J＝8.76Hz),8.09(1H,s).
Figure PCTCN2020131887-appb-000036
实施例29：中间体Ⅲ-12 3-氰基-3-(4-氯苯基)丙烯酸的合成
参照中间体3-氰基-3-苯基丙烯酸Ⅲ-7的合成方法，采用4-氯苯乙腈代替苯乙腈作为反应试剂，其他条件不变，中间体Ⅲ-12制得0.843g，产率81.2％。
ESI-MS：208.0[M+H] +。
反应式如下：
Figure PCTCN2020131887-appb-000037
实施例30：I-18的合成
参照化合物I-1的制备方法，用中间体Ⅲ-12替代3-苯基丙烯酸作为反应试剂，其他条件未变，制得目标化合物I-18浅黄褐色固体0.027g，产率30.3％。
ESI-MS：652.3[M+H] +,674.3[M+Na] +。
1H-NMR(300MHz,CDCl 3,TMS),δppm:0.88(3H,s),0.96(3H,s),1.04(3H,s),1.17(3H,s),1.26(3H,s),1.40(3H,s),1.45(3H,s),6.02(1H,s),7.23(1H,s),7.40(2H,d,J＝8.40Hz),7.64(2H,d,J＝8.43Hz),8.09(1H,s).
Figure PCTCN2020131887-appb-000038
实施例31：化合物的药理实验
采用四甲基氮唑蓝比色法(MTT法)对本发明化合物进行抗肿瘤活性测试，选取甲基巴多索隆(CDDO-Me)作为阳性对照药。
仪器：超净工作台(SW-CJ-1FD，AIRTECH，苏净安泰)、恒温CO 2培养箱(3111，Thermo，美国)、倒置生物显微镜(IX71，OLYMPUS，日本)、酶联免疫检测仪(Model680，BIO-RAD，美国)、平板摇床(Kylin-bell lab Instruments)、高压灭菌锅(YXO.SG41.280，上海华线)，离心机(SIGMA)。
试剂：DMEM(GIBCO)、胎牛血清(GIBCO)、胰蛋白酶(SIGMA)，DMSO(SIGMA)。
细胞株：人非小细胞肺癌细胞株A549，人肝癌细胞株HepG2，人乳腺癌细胞株MCF-7，人肾小管上皮细胞HK-2，大鼠胚胎心肌细胞H9C2(均由江苏凯基生物技术股份有限公司提供)。
方法：将冻存的细胞株复苏，置于恒温37℃CO 2培养箱中培养，每天换液一次，待其处于指数生长期状态良好时即可铺板。加入1ml 0.25％胰蛋白酶消化液，消化1-2min，在显微镜下观察细胞状态，当贴壁细胞变圆收缩时即可吸除消化液，加入1-2ml含10％胎牛血清的DMEM培养基制成细胞悬液，进行细胞计数，按照每孔5×10 4个细胞数及总孔数计算所需细胞悬液的量，将此细胞悬液接种于96孔板上，100μl/孔，周围用PBS液封，置于恒温37℃CO 2培养箱中培养24h。
用DMEM培养基配制受试药物、阳性对照药CDDO-Me、空白对照组DMSO，使其终浓 度为5μM/孔，每个药物3个复孔，培养48小时。将MTT试剂加入到96孔板中，10μl/孔，继续孵育4h。吸除板内培养基，每孔加入100μl DMSO，平板摇床振摇10min使结晶溶解。用酶联免疫检测仪在波长570nm处检测每孔的吸光值，并按下列公式计算细胞抑制率。3次初筛结果平均值为其最终抑制率，初筛抑制率大于60％的化合物进行浓度梯度筛选(5倍稀释)，以备计算受试药物的IC 50值(graphpad软件计算)，3次重复实验结果为所测化合物的最终IC 50值。
细胞抑制率％＝[(空白对照OD值－给药组OD值)/空白对照组OD值]×100％
表1本发明代表化合物对部分肿瘤细胞及心肌细胞增殖的抑制活性(IC 50，μM)
Figure PCTCN2020131887-appb-000039
由表1可知，本发明大部分化合物对心肌细胞H9C2的抑制活性大于CDDO-Me或与之相当。化合物I-1、I-2、I-3、I-4、I-5、I-6、I-7、I-8、I-9、I-12、I-13、I-14、I-16、I-18均表现出了对人肾小管上皮细胞HK-2更低的毒性。特别是化合物I-7和I-12对正常心肌细胞H9C2的抑制活性较小(IC 50值分别为3.176±1.74μM，3.143±1.53μM)，约为CDDO-Me(IC 50为0.308±0.01μM)的1/10，显示出较低的心肌毒性。
实施例32本发明化合物对荷瘤小鼠肿瘤的抑制作用
1)实验动物：6-8周雌性ICR小鼠，72只；实验细胞：S180腹水瘤细胞。
8只动物作为正常组，其余小鼠，采用下述方法造模。
2)S180腹水瘤细胞扩增与传代：取-80℃S180腹水瘤细胞与37℃水浴中溶化，置于12ml离心管中，加适量生理盐水，1200rpm离心5min，弃上清，加300μl生理盐水重悬细胞，腹腔注射至ICR小鼠，待小鼠腹部涨大，取此细胞腹腔注射至另一只ICR小鼠，待小鼠腹部涨大，即可用于接种。
3)小鼠腋下接种S180肿瘤细胞：取传至两代的S180细胞，离心，加生理盐水使浓度为1X10 7个/ml，腋下皮下注射100μl体积的细胞。建立小鼠荷瘤小鼠造模。
将模型小鼠分为荷瘤模型组、化合物1-7 5mg/kg组、化合物1-7 15mg/kg组、化合物1-125mg/kg组、化合物1-12 15mg/kg组、化合物1-16 5mg/kg组、化合物1-16 15mg/kg组、CDDO-Me15mg/kg组。
每组8只。
4)给药：待肿瘤长出，灌胃给药。
化合物1-7 5mg/kg组给予5mg/kg化合物1-7；
化合物1-7 15mg/kg组给予15mg/kg化合物1-7；
化合物1-12 5mg/kg组给予5mg/kg化合物1-12；
化合物1-12 15mg/kg组给予15mg/kg化合物1-12；
化合物1-16 5mg/kg组给予5mg/kg化合物1-16；
化合物1-16 15mg/kg组给予15mg/kg化合物1-16；
CDDO-Me 15mg/kg组给予15mg/kg化合物CDDO-Me
。
正常组、模型组给予等体积0.5％羧甲基纤维素钠。
连续给药7天，最后一次给药后的第二天剖检。
检测指标：称体重、脾重、肿瘤。冰上研磨脾脏，裂红，孵育FITC-CD11b、LY6C、LY6G抗体15min后上流式检测CD11b+LY6Chi+、CD11b+LY6G+。
实验结果见表1、表2。
表1本发明化合物对肿瘤的抑制作用
Figure PCTCN2020131887-appb-000040
注： #P和模型组相比P≤0.05， ##P和模型组相比P≤0.01， ###P和模型组相比P≤0.001；
*P和CDDO-Me组相比P≤0.05， **P和CDDO-Me组相比P≤0.01， ***P和CDDO-Me相比P≤0.001。
表2本发明化合物对M-MDSC、PMN-MDSC、脾脏指数的影响
Figure PCTCN2020131887-appb-000041
注： #P和模型组相比P≤0.05， ##P和模型组相比P≤0.01， ###P和模型组相比P≤0.001；
*P和CDDO-Me组相比P≤0.05， **P和CDDO-Me组相比P≤0.01， ***P和CDDO-Me相比P≤0.001。
MDSC是一组来源于髓系的不成熟细胞，正常情况下，它们可以分化为成熟的巨噬细胞，粒细胞和树突状细胞，病理情况下会聚集并活化，在肿瘤中，MDSC能抑制T细胞免疫反应，并能与其他免疫细胞相互作用，共同促进肿瘤微环境免疫抑制状态的形成。此外，MDSC还能通过破坏细胞外基质、促血管生成等非免疫途径来促进肿瘤的增殖与转移。吲哚胺2，3双加氧酶1(IDO1)是MDSC的重要功能标志之一，能催化肿瘤微环境中色氨酸代谢，导致可溶性犬尿氨酸及其下游代谢产物释放，诱导Treg及抗原呈递细胞免疫耐受，从而导致肿瘤免疫逃逸。有研究报道，MDSC参与胰腺癌、乳腺癌、脑转移瘤等的进展，MDSC作为一个潜在的治疗靶点和可靠的预后标志，具有极大的研究价值。
本发明实施例研究发现本发明化合物能够抑制MDSC的表达，可以改善肿瘤微环境，提示对于肺癌、肝癌、胰腺癌、乳腺癌、腹水瘤、脑转移瘤等具有治疗作用。
此外，需要说明的是，实施例32所选的化合物是对本发明所述目标化合物的代表举例，而不是对本发明的限制。

Claims (12)

  1. 式I化合物或其药学上可接受的盐：
    Figure PCTCN2020131887-appb-100001
    其中，R 1、R 2、R 3分别独立地选自以下取代基：H，C1-6烷基，C1-6烷氧基，卤素，氰基，被卤素或氰基取代的C1-6烷基；优选H，C1-3烷基，C1-3烷氧基，卤素，氰基，被卤素或氰基取代的C1-3烷基。
  2. 如权利要求1所述化合物或其药学上可接受的盐，其特征在于，所述R 1、R 2分别独立地选自H或氰基；R 3选自H，C1-3烷基，烷氧基，卤素，被卤素取代的C1-3烷基；所述烷氧基为含1-3个碳原子的烷氧基；所述卤素选自F，Cl，Br，I。
  3. 如权利要求1所述化合物或其药学上可接受的盐，其特征在于，所述R 1为H或氰基，R 2为H或氰基，R 3选自H、甲基、甲氧基、三氟甲基、Cl或F。
  4. 如权利要求1所述化合物或其药学上可接受的盐，其特征在于，所述R 1为H或氰基，R 2为H或氰基，R 3为Cl、H或三氟甲基。
  5. 如权利要求1所述化合物或其药学上可接受的盐，其特征在于，所述化合物选自：
    3-苯基-N-(2-氰基-3,12-二氧代齐墩果烷-1,9(11)-二烯-19-基)丙烯酰胺，
    3-(4-甲基苯基)-N-(2-氰基-3,12-二氧代齐墩果烷-1,9(11)-二烯-19-基)丙烯酰胺，
    3-(4-甲氧基苯基)-N-(2-氰基-3,12-二氧代齐墩果烷-1,9(11)-二烯-19-基)丙烯酰胺，
    3-(4-三氟甲基苯基)-N-(2-氰基-3,12-二氧代齐墩果烷-1,9(11)-二烯-19-基)丙烯酰胺，
    3-(4-氟苯基)-N-(2-氰基-3,12-二氧代齐墩果烷-1,9(11)-二烯-19-基)丙烯酰胺，
    3-(4-氯苯基)-N-(2-氰基-3,12-二氧代齐墩果烷-1,9(11)-二烯-19-基)丙烯酰胺，
    2-氰基-3-基苯基-N-(2-氰基-3,12-二氧代齐墩果烷-1,9(11)-二烯-19-基)丙烯酰胺，
    2-氰基-3-(4-甲基苯基)-N-(2-氰基-3,12-二氧代齐墩果烷-1,9(11)-二烯-19-基)丙烯酰胺，
    2-氰基-3-(4-甲氧基苯基)-N-(2-氰基-3,12-二氧代齐墩果烷-1,9(11)-二烯-19-基)丙烯酰胺，
    2-氰基-3-(4-三氟甲基苯基)-N-(2-氰基-3,12-二氧代齐墩果烷-1,9(11)-二烯-19-基)丙烯酰胺，
    2-氰基-3-(4-氟苯基)-N-(2-氰基-3,12-二氧代齐墩果烷-1,9(11)-二烯-19-基)丙烯酰胺，
    2-氰基-3-(4-氯苯基)-N-(2-氰基-3,12-二氧代齐墩果烷-1,9(11)-二烯-19-基)丙烯酰胺，
    3-苯基-3-氰基-N-(2-氰基-3,12-二氧代齐墩果烷-1,9(11)-二烯-19-基)丙烯酰胺，
    3-(4-甲基苯基)-3-氰基-N-(2-氰基-3,12-二氧代齐墩果烷-1,9(11)-二烯-19-基)丙烯酰胺，
    3-(4-甲氧基苯基)-3-氰基-N-(2-氰基-3,12-二氧代齐墩果烷-1,9(11)-二烯-19-基)丙烯酰胺，
    3-(4-三氟甲基苯基)-3-氰基-N-(2-氰基-3,12-二氧代齐墩果烷-1,9(11)-二烯-19-基)丙烯酰胺，
    3-(4-氟苯基)-3-氰基-N-(2-氰基-3,12-二氧代齐墩果烷-1,9(11)-二烯-19-基)丙烯酰胺，
    3-(4-氯苯基)-3-氰基-N-(2-氰基-3,12-二氧代齐墩果烷-1,9(11)-二烯-19-基)丙烯酰胺。
  6. 一种如权利要求1-5中任一项所述式I化合物的合成方法，其特征在于，合成方法如下：
    式Ⅱ与式Ⅲ经缩合反应制得式Ⅰ化合物，
    Figure PCTCN2020131887-appb-100002
    其中，所述R 1、R 2、R 3的限定如权利要求1-5中任一项所述，所述缩合剂选自二环己基碳二亚胺、N,N-二异丙基碳二亚胺、1-乙基-(3-二甲基氨基丙基)碳酰二亚胺、苯并三氮唑-1-基氧基三(二甲基氨基)磷鎓六氟磷酸盐或六氟磷酸苯并三唑-1-基-氧基三吡咯烷中的一种或多种。
  7. 一种如权6所述的合成方法，其特征在于，所述式II的合成方法如下：
    Figure PCTCN2020131887-appb-100003
    将CDDO进行Curtius重排得到C-17位氨基化的衍生物，即式II。
  8. 一种药物组合物，包含权利要求1-5中任一项所述化合物或其药学上可接受的盐，和一种或多种药学上可接受的药用辅料。
  9. 如权利要求1-5中任一项所述化合物或其药学上可接受的盐或权利要求8所述的药物组合物在制备药物中的用途，所述药物用于治疗肿瘤。
  10. 如权利要求9所述的用途，其中所述肿瘤选自肺癌、肝癌、腹水瘤、脑转移瘤、结肠癌、胰腺癌、乳腺癌、前列腺癌、脑癌、卵巢癌、宫颈癌、睾丸癌、肾癌、头颈癌、淋巴癌、黑色素瘤或白血病；优选选自肺癌、肝癌、乳腺癌、腹水瘤、胰腺癌、脑转移瘤；更优选选自非小细胞肺癌、肝癌、乳腺癌、腹水瘤。
  11. 一种治疗肿瘤的方法，包括将治疗有效量的如权利要求1-5中任一项所述化合物或其药学上可接受的盐或权利要求8所述的药物组合物施用于受试者或患者。
  12. 如权利要求11所述的方法，其中所述肿瘤选自肺癌、肝癌、腹水瘤、脑转移瘤、结肠癌、胰腺癌、乳腺癌、前列腺癌、脑癌、卵巢癌、宫颈癌、睾丸癌、肾癌、头颈癌、淋巴癌、黑 色素瘤或白血病；优选选自肺癌、肝癌、乳腺癌、腹水瘤、胰腺癌、脑转移瘤；更优选选自非小细胞肺癌、肝癌、乳腺癌、腹水瘤。
PCT/CN2020/131887 2019-11-27 2020-11-26 一种齐墩果烷苯丙烯酰胺衍生物及其制备方法和用途 WO2021104391A1 (zh)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2022531563A JP2023504428A (ja) 2019-11-27 2020-11-26 オレアナンシンナムアミド誘導体及びその製造方法と用途
EP20894763.0A EP4067367A4 (en) 2019-11-27 2020-11-26 OLEANANE CINNAMAMIDE DERIVATIVE, ITS PREPARATION METHOD AND ITS USE
KR1020227018564A KR20220104734A (ko) 2019-11-27 2020-11-26 올레아난 신남아미드 유도체 및 이의 제조 방법과 용도
CN202080079360.9A CN114729001A (zh) 2019-11-27 2020-11-26 一种齐墩果烷苯丙烯酰胺衍生物及其制备方法和用途
US17/779,165 US20230023332A1 (en) 2019-11-27 2020-11-26 Olean-phenylacrylamide derivative, method for preparing same, and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201911182967 2019-11-27
CN201911182967.5 2019-11-27

Publications (1)

Publication Number Publication Date
WO2021104391A1 true WO2021104391A1 (zh) 2021-06-03

Family

ID=76130022

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/131887 WO2021104391A1 (zh) 2019-11-27 2020-11-26 一种齐墩果烷苯丙烯酰胺衍生物及其制备方法和用途

Country Status (6)

Country Link
US (1) US20230023332A1 (zh)
EP (1) EP4067367A4 (zh)
JP (1) JP2023504428A (zh)
KR (1) KR20220104734A (zh)
CN (1) CN114729001A (zh)
WO (1) WO2021104391A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009146216A2 (en) * 2008-04-18 2009-12-03 Reata Pharmaceuticals. Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
CN102083442A (zh) * 2008-04-18 2011-06-01 里亚塔医药公司 抗氧化剂炎症调节剂：在c-17具有氨基和其它修饰的齐墩果酸衍生物
CN105517554A (zh) * 2013-08-23 2016-04-20 里亚塔医药公司 使用甲基巴多索隆或其类似物治疗和预防内皮功能障碍的方法
CN106632576A (zh) * 2016-12-16 2017-05-10 中国药科大学 2－氰基－3，12－二氧代齐墩果烷－1，9（11）－二烯－28－羧酸的合成方法改进

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10953020B2 (en) * 2016-11-08 2021-03-23 Reata Pharmaceuticals, Inc. Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009146216A2 (en) * 2008-04-18 2009-12-03 Reata Pharmaceuticals. Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
CN102083442A (zh) * 2008-04-18 2011-06-01 里亚塔医药公司 抗氧化剂炎症调节剂：在c-17具有氨基和其它修饰的齐墩果酸衍生物
CN105517554A (zh) * 2013-08-23 2016-04-20 里亚塔医药公司 使用甲基巴多索隆或其类似物治疗和预防内皮功能障碍的方法
CN106632576A (zh) * 2016-12-16 2017-05-10 中国药科大学 2－氰基－3，12－二氧代齐墩果烷－1，9（11）－二烯－28－羧酸的合成方法改进

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Remingtong's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY, pages: 1418
CAREYSUNDBERG: "ADVANCED ORGANIC CHEMISTRY", vol. A, B, 2000, PLENUM PRESS
JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, no. 2, 1977
See also references of EP4067367A4

Also Published As

Publication number Publication date
CN114729001A (zh) 2022-07-08
EP4067367A4 (en) 2024-04-10
US20230023332A1 (en) 2023-01-26
EP4067367A1 (en) 2022-10-05
JP2023504428A (ja) 2023-02-03
KR20220104734A (ko) 2022-07-26

Similar Documents

Publication Publication Date Title
WO2022143473A1 (zh) 一种核苷类化合物及其用途
JP5611344B2 (ja) アゴメラチン及びその薬物組成物
CN102083849B (zh) 胆甾-4-烯-3-酮肟的衍生物、包含其的药物组合物以及制备方法
MX2015002602A (es) Derivados de imidazolina, metodos de preparacion de los mismos, y sus aplicaciones en medicina.
JP2008525525A (ja) グルココルチコイドミメティクス、その製法、医薬組成物及び使用
US6172099B1 (en) Tricyclic compounds having saturated rings and medicinal compositions containing the same
WO2016086824A1 (zh) 一种Bouchardatine和Bouchardatine衍生物及其制备方法和应用
CN111704646B (zh) 甾体类化合物及其制备方法和用途
MX2015003151A (es) Compuestos cristalinos.
WO2001044187A1 (fr) Nouveaux composes tricycliques substitues
WO2022206705A1 (zh) 作为tyk2假激酶结构域抑制剂的杂环化合物及合成方法和用途
JP2022553833A (ja) エストロゲン受容体調節薬の塩及び形態
WO2021104391A1 (zh) 一种齐墩果烷苯丙烯酰胺衍生物及其制备方法和用途
WO2015055114A1 (zh) 二苯乙烷衍生物及其应用
JP3471778B2 (ja) 三環性縮合複素環化合物、その製造方法および用途
CN108947904B (zh) 一种含有七元内酰胺环的化合物及其应用
WO2019184919A1 (zh) 一种含有金刚烷的化合物及其在治疗癌症中的用途
JP2022516922A (ja) フッ素含有置換ベンゾチオフェン化合物ならびにその医薬組成物および応用
WO2016138882A1 (zh) 七元环小檗碱类似物及其药物组合物、制备方法和用途
KR20020072782A (ko) 이소인돌로인돌론 화합물, 이들의 제조 방법, 및 이들을함유하는 약제 조성물
EP3447045B9 (en) 1-(1-hydroxy-2,3-dihydro-1h-inden-5-yl)-urea derivatives and related compounds kcnq 2-5 channel activators for treating dysuria
WO2023145873A1 (ja) リゾホスファチジルセリン類似体、及びリゾホスファチジルセリン類似体を含む線維症を治療又は予防するための医薬組成物
CN102267952A (zh) 喹唑啉类化合物、其制备方法和用途
WO2023070373A1 (zh) 一类多环聚酮化合物在制备抗新型冠状病毒药物中的应用
WO2020007329A1 (zh) Hdac6选择性抑制剂的晶型及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20894763

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2022531563

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20227018564

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020894763

Country of ref document: EP

Effective date: 20220627